1. Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis
   Long Jiang et al, 2019, European Journal of Surgical Oncology CrossRef
2. Clinical usefulness of the 3-tier classification according to the proportion of morphological patterns for patients with pathological stage I invasive lung adenocarcinoma
   Junichiro Osawa et al, 2021, General Thoracic and Cardiovascular Surgery CrossRef
3. Correlation between epidermal growth factor receptor mutation and histologic subtypes or characteristics of computed tomography findings in patients with resected pulmonary adenocarcinoma
   Danyun Wang et al, 2018, Journal of Cancer Research and Therapeutics CrossRef
4. Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens
   Long Zhao et al, 2017, Medicine CrossRef
5. Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India
   Varsha Singh et al, 2019, Current Problems in Cancer CrossRef
6. Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
   Mio Mori et al, 2019, Thoracic Cancer CrossRef
7. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma
   Thinh T. Nguyen et al, 2022, Genome Medicine CrossRef
8. Predicting EGFR gene mutation status in lung adenocarcinoma based on multifeature fusion
   Yanyun Jiang et al, 2023, Biomedical Signal Processing and Control CrossRef
9. Examination of Driver Mutation-Specific MicroRNA Expression in Human Lung Adenocarcinoma Cell Lines
   Sayaka Kobayashi et al, 2024, The Kitakanto Medical Journal CrossRef
10. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients
    Zhaoxuan Zhang et al, 2017, Tumor Biology CrossRef
11. Individualized nomogram for predicting ALK rearrangement status in lung adenocarcinoma patients
    Lan Song et al, 2021, European Radiology CrossRef
12. Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non‐small cell lung cancer
    Candice C. Poon et al, 2017, International Journal of Cancer CrossRef
13. Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients
    Lanlan Liu et al, 2021, Current Oncology CrossRef
14. Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement
    Qiongqiong Gao et al, 2017, Oncotarget CrossRef
15. Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma
    Jianfu Li et al, 2024, Neoplasia CrossRef
16. Recent application of artificial intelligence on histopathologic image-based prediction of gene mutation in solid cancers
    Mohammad Rizwan Alam et al, 2023, Briefings in Bioinformatics CrossRef
17. Prognostic implications, genomic and immune characteristics of lung adenocarcinoma with lepidic growth pattern
    Yue Li et al, 2024, Journal of Clinical Pathology CrossRef
18. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma
    Yuki Matsumura et al, 2017, Interactive CardioVascular and Thoracic Surgery CrossRef
19. Molecular Pathology of Lung Cancer
    James J. Saller et al, 2022, Cold Spring Harbor Perspectives in Medicine CrossRef
20. Clinical significance of the cribriform pattern in invasive adenocarcinoma of the lung
    Ruizhen Zhang et al, 2019, Journal of Clinical Pathology CrossRef